Literature DB >> 16428249

Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial.

J Athene Lane1, Liam J Murray, Sian Noble, Matthias Egger, Ian M Harvey, Jenny L Donovan, Prakash Nair, Richard F Harvey.   

Abstract

OBJECTIVE: To determine the impact of a community based Helicobacter pylori screening and eradication programme on the incidence of dyspepsia, resource use, and quality of life, including a cost consequences analysis.
DESIGN: H pylori screening programme followed by randomised placebo controlled trial of eradication.
SETTING: Seven general practices in southwest England. PARTICIPANTS: 10,537 unselected people aged 20-59 years were screened for H pylori infection (13C urea breath test); 1558 of the 1636 participants who tested positive were randomised to H pylori eradication treatment or placebo, and 1539 (99%) were followed up for two years. INTERVENTION: Ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for two weeks or placebo. MAIN OUTCOME MEASURES: Primary care consultation rates for dyspepsia (defined as epigastric pain) two years after randomisation, with secondary outcomes of dyspepsia symptoms, resource use, NHS costs, and quality of life.
RESULTS: In the eradication group, 35% fewer participants consulted for dyspepsia over two years compared with the placebo group (55/787 v 78/771; odds ratio 0.65, 95% confidence interval 0.46 to 0.94; P = 0.021; number needed to treat 30) and 29% fewer participants had regular symptoms (odds ratio 0.71, 0.56 to 0.90; P = 0.05). NHS costs were 84.70 pounds sterling (74.90 pounds sterling to 93.91 pounds sterling) greater per participant in the eradication group over two years, of which 83.40 pounds sterling (146 dollars; 121 euro) was the cost of eradication treatment. No difference in quality of life existed between the two groups.
CONCLUSIONS: Community screening and eradication of H pylori is feasible in the general population and led to significant reductions in the number of people who consulted for dyspepsia and had symptoms two years after treatment. These benefits have to be balanced against the costs of eradication treatment, so a targeted eradication strategy in dyspeptic patients may be preferable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16428249      PMCID: PMC1352048          DOI: 10.1136/bmj.38702.662546.55

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  26 in total

Review 1.  Is economic evaluation in touch with society's health values?

Authors:  Joanna Coast
Journal:  BMJ       Date:  2004-11-20

2.  Development of a postal health status questionnaire to identify people with dyspepsia in the general population.

Authors:  T Kennedy; R Jones
Journal:  Scand J Prim Health Care       Date:  1995-12       Impact factor: 2.581

Review 3.  Dyspepsia: a dilemma for doctors?

Authors:  R V Heatley; B J Rathbone
Journal:  Lancet       Date:  1987-10-03       Impact factor: 79.321

4.  Effect of Helicobacter pylori eradication therapy on dyspeptic symptoms in primary care.

Authors:  F D Hobbs; B C Delaney; M Rowsby; J E Kenkre
Journal:  Fam Pract       Date:  1996-06       Impact factor: 2.267

5.  Endoscopy for Helicobacter pylori sero-negative young dyspeptic patients: an economic evaluation based on a randomized trial.

Authors:  M Asante; J Lord; M Mendall; T Northfield
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-08       Impact factor: 2.566

6.  Results of Helicobacter pylori screening and eradication in a multi-ethnic community in central England.

Authors:  M A Stone; H Patel; K K Panja; D B Barnett; J F Mayberry
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-11       Impact factor: 2.566

7.  Validating the SF-36 health survey questionnaire: new outcome measure for primary care.

Authors:  J E Brazier; R Harper; N M Jones; A O'Cathain; K J Thomas; T Usherwood; L Westlake
Journal:  BMJ       Date:  1992-07-18

8.  Prevalence of symptoms of dyspepsia in the community.

Authors:  R Jones; S Lydeard
Journal:  BMJ       Date:  1989-01-07

9.  Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project.

Authors:  Richard F Harvey; J Athene Lane; Liam J Murray; Ian M Harvey; Jenny L Donovan; Prakash Nair
Journal:  BMJ       Date:  2004-05-04

10.  The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.

Authors:  H Rosengren; R J Polson
Journal:  Br J Gen Pract       Date:  1996-03       Impact factor: 5.386

View more
  18 in total

1.  Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

Authors:  Yi-Chia Lee; Jyh-Ming Liou; Ming-Shiang Wu; Chun-Ying Wu; Jaw-Town Lin
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

2.  Who benefits from Helicobacter pylori eradication?

Authors:  Brendan C Delaney
Journal:  BMJ       Date:  2006-01-28

Review 3.  Dyspepsia and Helicobacter pylori.

Authors:  Rupal Shah
Journal:  BMJ       Date:  2007-01-06

Review 4.  Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations.

Authors:  Dyfrig A Hughes; Lesley Tilson; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  Quality of life in patients with functional dyspepsia: Short- and long-term effect of Helicobacter pylori eradication with pantoprazole, amoxicillin, and clarithromycin or cisapride therapy: A prospective, parallel-group study.

Authors:  György M Buzás
Journal:  Curr Ther Res Clin Exp       Date:  2006-09

Review 6.  Population screening and treatment of Helicobacter pylori infection.

Authors:  Anthony O'Connor; Colm A O'Morain; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-05       Impact factor: 46.802

7.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

Review 8.  Contemplating the future without Helicobacter pylori and the dire consequences hypothesis.

Authors:  David Y Graham; Yoshio Yamaoka; Hoda M Malaty
Journal:  Helicobacter       Date:  2007-11       Impact factor: 5.753

Review 9.  Managing dyspepsia.

Authors:  Alexander C Ford; Paul Moayyedi
Journal:  Curr Gastroenterol Rep       Date:  2009-08

10.  Non-invasive diagnosis of H pylori infection: evaluation of serological tests with and without current infection marker CIM.

Authors:  Sufi-H Z Rahman; M-Golam Azam; M-Anisur Rahman; M-S Arfin; M-Mahbub Alam; Tareq-M Bhuiyan; Nasim Ahmed; Motiur Rahman; Shamsun Nahar; M-S Hassan
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.